# Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies

> **NCT01921387** · PHASE1,PHASE2 · COMPLETED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 20 (actual)

## Conditions studied

- Recurrent B-Cell Non-Hodgkin Lymphoma
- Recurrent Hodgkin Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent T-Cell Non-Hodgkin Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma
- Refractory Mantle Cell Lymphoma
- Refractory T-Cell Non-Hodgkin Lymphoma

## Interventions

- **PROCEDURE:** Autologous Hematopoietic Stem Cell Transplantation
- **DRUG:** Carmustine
- **DRUG:** Cytarabine
- **DRUG:** Etoposide
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Melphalan
- **PROCEDURE:** Peripheral Blood Stem Cell Transplantation
- **RADIATION:** Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8

## Key facts

- **NCT ID:** NCT01921387
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-09
- **Primary completion:** 2017-07-26
- **Final completion:** 2020-07-26
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2020-08-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01921387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01921387, "Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01921387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*